Literature DB >> 28826027

CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.

Xiaobing Qing1, Jonas Walter1, Javier Jarazo1, Jonathan Arias-Fuenzalida1, Anna-Lena Hillje1, Jens C Schwamborn2.   

Abstract

The p.G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) has been identified as the most prevalent genetic cause of familial and sporadic Parkinson's disease (PD). The Cre-LoxP recombination system has been used to correct the LRRK2-G2019S mutation in patient derived human induced pluripotent stem cells (hiPSCs) in order to generate isogenic controls. However, the remaining LoxP site can influence gene expression. In this study, we report the generation of a footprint-free LRRK2-G2019S isogenic hiPS cell line edited with the CRISPR/Cas9 and piggyBac technologies. We observed that the percentage of Tyrosine Hydroxylase (TH) positive neurons with a total neurite length of >2000μm was significantly reduced in LRRK2-G2019S dopaminergic (DA) neurons. The average branch number in LRRK2-G2019S DA neurons was also decreased. In addition, we have shown that in vitro TH positive neurons with a total neurite length of >2000μm were positive for Serine 129 phosphorylated (S129P) alpha-Synuclein (αS) and we hypothesize that S129P-αS plays a role in the maintenance or formation of long neurites. In summary, our footprint-free LRRK2-G2019S isogenic cell lines allow standardized, genetic background independent, in vitro PD modeling and provide new insights into the role of LRRK2-G2019S and S129P-αS in the pathogenesis of PD.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; LRRK2-G2019S; Parkinson's disease; Serine129 phosphorylated α-Synuclein; hiPS; piggyBac; α-Synuclein

Mesh:

Substances:

Year:  2017        PMID: 28826027     DOI: 10.1016/j.scr.2017.08.013

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  27 in total

Review 1.  Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.

Authors:  Jenne Tran; Helena Anastacio; Cedric Bardy
Journal:  NPJ Parkinsons Dis       Date:  2020-04-24

Review 2.  Stem cells technology: a powerful tool behind new brain treatments.

Authors:  Lucienne N Duru; Zhenzhen Quan; Talal Jamil Qazi; Hong Qing
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 3.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 4.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

Review 5.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

Review 6.  Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.

Authors:  S L Sison; S C Vermilyea; M E Emborg; A D Ebert
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-04       Impact factor: 5.081

7.  Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci.

Authors:  Renjitha Gopurappilly
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Basic and Preclinical Research for Personalized Medicine.

Authors:  Wanda Lattanzi; Cristian Ripoli; Viviana Greco; Marta Barba; Federica Iavarone; Angelo Minucci; Andrea Urbani; Claudio Grassi; Ornella Parolini
Journal:  J Pers Med       Date:  2021-04-29

Review 9.  Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells.

Authors:  Elizabeth A LaMarca; Samuel K Powell; Schahram Akbarian; Kristen J Brennand
Journal:  Front Pediatr       Date:  2018-04-03       Impact factor: 3.418

Review 10.  Representing Diversity in the Dish: Using Patient-Derived in Vitro Models to Recreate the Heterogeneity of Neurological Disease.

Authors:  Layla T Ghaffari; Alexander Starr; Andrew T Nelson; Rita Sattler
Journal:  Front Neurosci       Date:  2018-02-09       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.